JP2023521161A - 臓器傷害の予防及び処置 - Google Patents

臓器傷害の予防及び処置 Download PDF

Info

Publication number
JP2023521161A
JP2023521161A JP2022561995A JP2022561995A JP2023521161A JP 2023521161 A JP2023521161 A JP 2023521161A JP 2022561995 A JP2022561995 A JP 2022561995A JP 2022561995 A JP2022561995 A JP 2022561995A JP 2023521161 A JP2023521161 A JP 2023521161A
Authority
JP
Japan
Prior art keywords
injury
infection
respiratory
compound
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022561995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521161A5 (cg-RX-API-DMAC7.html
Inventor
チン‐ポン マック,
ファシュー マー,
ドング シャオ,
マイケル ピール,
ハンス フリリ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farsight Medical Technology Shanghai Co Ltd
Original Assignee
Farsight Medical Technology Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farsight Medical Technology Shanghai Co Ltd filed Critical Farsight Medical Technology Shanghai Co Ltd
Publication of JP2023521161A publication Critical patent/JP2023521161A/ja
Publication of JP2023521161A5 publication Critical patent/JP2023521161A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022561995A 2020-04-15 2021-04-15 臓器傷害の予防及び処置 Pending JP2023521161A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/084820 2020-04-15
CN2020084820 2020-04-15
CNPCT/CN2021/081574 2021-03-18
CN2021081574 2021-03-18
PCT/CN2021/087501 WO2021209003A1 (en) 2020-04-15 2021-04-15 Prevention and treatment of organ injuries

Publications (2)

Publication Number Publication Date
JP2023521161A true JP2023521161A (ja) 2023-05-23
JP2023521161A5 JP2023521161A5 (cg-RX-API-DMAC7.html) 2024-04-24

Family

ID=78085285

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022561995A Pending JP2023521161A (ja) 2020-04-15 2021-04-15 臓器傷害の予防及び処置

Country Status (9)

Country Link
US (1) US12465629B2 (cg-RX-API-DMAC7.html)
EP (1) EP4135743A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023521161A (cg-RX-API-DMAC7.html)
KR (1) KR20230002589A (cg-RX-API-DMAC7.html)
CN (2) CN114245744A (cg-RX-API-DMAC7.html)
AU (1) AU2021256222A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174545A1 (cg-RX-API-DMAC7.html)
TW (1) TWI889805B (cg-RX-API-DMAC7.html)
WO (1) WO2021209003A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08298986A (ja) * 1995-04-28 1996-11-19 Asahi Chem Ind Co Ltd ホスホリパーゼa2酵素
WO2019016572A1 (en) * 2017-07-21 2019-01-24 Cypralis Ltd CICLOSPORINE ANALOGUES AND USES THEREOF

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
ATE254630T1 (de) 1998-06-12 2003-12-15 Chem Ag C Cyclosporine
CN101068829B (zh) 2004-10-01 2012-05-30 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
BRPI0708424A2 (pt) 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
CA2652662C (en) * 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
MX350746B (es) * 2010-12-03 2017-09-14 Hebei Kunxiangjishi Pharmaceutical Tech Co Ltd Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
GB201217560D0 (en) 2012-10-02 2012-11-14 Mitopharm Ltd Novel cyclic depsipeptide compounds and their uses
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Mebmt側鏈已環化之環孢菌素衍生物
CN105983095B (zh) * 2015-02-15 2019-09-13 艾棣维欣(苏州)生物制药有限公司 一种呼吸道合胞体病毒疫苗及其制备方法与应用
CN106902346A (zh) 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 药物组合物及其制药用途
CN106902347A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 亲环孢素抑制剂的用途
CN111449050A (zh) 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) * 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
WO2021190603A1 (en) 2020-03-26 2021-09-30 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08298986A (ja) * 1995-04-28 1996-11-19 Asahi Chem Ind Co Ltd ホスホリパーゼa2酵素
WO2019016572A1 (en) * 2017-07-21 2019-01-24 Cypralis Ltd CICLOSPORINE ANALOGUES AND USES THEREOF

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"タゾバクタム/ピペラシリン、ペニシリン系", 抗菌薬インターネットブック, JPN6025033035, 2012, ISSN: 0005667951 *
BIOCHIMICA ET BIOPHYSICA ACTA, JPN6025006681, 2015, pages 2563 - 2573, ISSN: 0005532710 *

Also Published As

Publication number Publication date
TW202143995A (zh) 2021-12-01
CA3174545A1 (en) 2021-10-21
CN113694177B (zh) 2022-06-17
AU2021256222A1 (en) 2022-10-06
EP4135743A4 (en) 2024-05-22
CN113694177A (zh) 2021-11-26
US20230181680A1 (en) 2023-06-15
WO2021209003A1 (en) 2021-10-21
KR20230002589A (ko) 2023-01-05
EP4135743A1 (en) 2023-02-22
TWI889805B (zh) 2025-07-11
US12465629B2 (en) 2025-11-11
CN114245744A (zh) 2022-03-25

Similar Documents

Publication Publication Date Title
US20090197941A1 (en) Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease
TWI889805B (zh) 器官損傷的預防和治療
CN118806741B (zh) 二氢青蒿酸在制备预防或治疗急性肺损伤的药物中的应用
EP2608783A1 (en) Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
EP4346789B1 (en) Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
US11534398B2 (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
US8420697B2 (en) Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
CN112121045A (zh) 肺炎患儿纤支镜手术用麻醉抗炎药物组合物和麻醉抗炎的方法
RU2451507C2 (ru) Лекарственное средство для лечения хронического обструктивного заболевания легких
TW202504602A (zh) 用於治療臟器纖維化相關疾病的藥物組合物和方法
JP2016027032A (ja) 慢性閉塞性肺疾患治療剤
EA052469B1 (ru) Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов
RU2600822C1 (ru) Способ лечения хронического обструктивного бронхита
US20220054509A1 (en) Methods of treatment for disease from coronavirus exposure
Dal Negro et al. Use of aerosols in bronchiectasis patients
Oswald Chronic coughing in dogs and cats-my favorite drugs.
HK1166934A (en) Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
KR20130038583A (ko) 소포체 스트레스 억제제를 유효성분으로 함유하는 급성 폐 손상의 예방 또는 치료용 약학 조성물
JP2023158351A (ja) コロナウイルス感染症の後遺症を処置または予防するための医薬組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219